白血病骨髓基质增强HL-60细胞抵抗IDA化疗药物研究

为了研究造血微环境异常在残留白血病发生中的作用和机制 ,采用Dexter型骨髓培养体系形成白血病骨髓基质细胞贴壁层 ,接种HL 6 0细胞共培养 ,用去甲氧基柔红霉素 (IDA)处理 ,观察HL 6 0细胞的活性变化。结果表明 :随着IDA剂量的增加及培养时间的延长 ,HL 6 0细胞活性逐渐减弱 ,与白血病骨髓基质共培养的HL 6 0细胞数明显高于正常对照组 (P <0 .0 5 ) ,骨髓基质细胞层或单纯基质细胞条件培养液体外使IDA对HL 6 0细胞杀伤能力减弱。结论 :白血病骨髓基质有助于HL 6 0细胞抵抗化疗药物 ,对残留白血病的发展具有一定作用。

Effects of Leukemia Bone Marrow Stromal Cells on Resistance of Co-cultured HL-60 to Idarubicin

To study the role of hematopoietic microenvironment abnormality in development of minimal residual disease and its mechanism, the viability of HL 60 cells was investigated by means of bone marrow stromal cell culture system or co culture system of bone marrow stromal cell with HL 60 cells and idarubicin (IDA), flow cytometry and ELISA. The results showed that viability of HL 60 cells gradually decreased along with the inerase of IDA dose and prolongation of culture time. Amount of HL 60 cells co cultured with leukemia bone marrow stramal cells was significantly increased as compared with that of the control (P<0.05). Bone marrow stromal cells or stromal cell conditioned medium reduced the effect of IDA on HL 60 cells in culture. In conclusion, leukemia bone marrow stromal cells contribute to increasing resistance of HL 60 cells to chemotherapentic agents, and play some role in developing minimal residual disease.